Left Ventricular Tonic Contraction as a Novel Biomarker of Cardiomyopathy in Duchenne Muscular Dystrophy
详细信息 查看全文
- 作者：Jennifer A. Su ; Leigh Ramos-Platt ; JonDavid Menteer
- 关键词：Duchenne muscular dystrophy ; Dilated cardiomyopathy ; ACE inhibition ; Biomarker ; Pediatrics ; Prophylaxis
- 刊名：Pediatric Cardiology
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：37
- 期：4
- 页码：678-685
- 全文大小：747 KB
- 参考文献：1.Alderton JM, Steinhardt RA (2000) How calcium influx through calcium leak channels is responsible for the elevated levels of calcium-dependent proteolysis in dystrophic myotubes. Trends Cardiovasc Med 10(6):268–272CrossRef PubMed
2.Ameen V, Robson LG (2010) Experimental models of duchenne muscular dystrophy: relationship with cardiovascular disease. Open Cardiovasc Med J 4:265–277CrossRef PubMed PubMedCentral
3.Bauer R, Straub V, Blain A, Bushby K, MacGowan GA (2009) Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. Eur J Heart Fail 11(5):463–471CrossRef PubMed
4.Berchtold MW, Brinkmeier H, Müntener M (2000) Calcium ion in skeletal muscle: its crucial role for muscle function, plasticity, and disease. Physiol Rev 80(3):1215–1265PubMed
5.Blain A, Greally E, Laval S, Blamire A, Straub V, MacGowan GA (2013) Beta-blockers, left and right ventricular function, and in vivo calcium influx in muscular dystrophy cardiomyopathy. PLoS One 8(2):e57260CrossRef PubMed PubMedCentral
6.Calabrò R, Pisacane C, Pacileo G, Russo MG (1999) Hemodynamic effects of a single oral dose of enalapril among children with asymptomatic chronic mitral regurgitation. Am Heart J 138(5 Pt 1):955–961CrossRef PubMed
7.Carlson CG (1998) The dystrophinopathies: an alternative to the structural hypothesis. Neurobiol Dis 5(1):3–15CrossRef PubMed
8.Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57(6):450–458CrossRef PubMed
9.Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Bécane HM (2005) Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 45(6):855–857CrossRef PubMed
10.Duboc D, Meune C, Pierre B, Wahbi K, Eymard B, Toutain A, Berard C, Vaksmann G, Weber S, Bécane HM (2007) Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years’ follow-up. Am Heart J 154(3):596–602CrossRef PubMed
11.Goodwin FC, Muntoni F (2005) Cardiac involvement in muscular dystrophies: molecular mechanisms. Muscle Nerve 32(5):577–588CrossRef PubMed
12.Greally E, Davison BJ, Blain A, Laval S, Blamire A, Straub V, MacGowan GA (2013) Heterogenous abnormalities of in vivo left ventricular calcium influx and function in mouse models of muscular dystrophy cardiomyopathy. J Cardiovasc Magn Reson 15:4CrossRef PubMed PubMedCentral
13.Head SI, Williams DA, Stephenson DG (1992) Abnormalities in structure and function of limb skeletal muscle fibres of dystrophic mdx mice. Proc Biol Sci 248(1322):163–169CrossRef PubMed
14.Hor KN, Kissoon N, Mazur W, Gupta R, Ittenbach RF, Al-Khalidi HR, Cripe LH, Raman SV, Puchalski MD, Gottliebson WM, Benson DW (2015) Regional circumferential strain is a biomarker for disease severity in Duchenne muscular dystrophy heart disease: a cross-sectional study. Pediatr Cardiol 36(1):111–119CrossRef PubMed
15.Markham LW, Michelfelder EC, Border WL, Khoury PR, Spicer RL, Wong BL, Benson DW, Cripe LH (2006) Abnormalities of diastolic function precede dilated cardiomyopathy associated with Duchenne muscular dystrophy. J Am Soc Echocardiogr 19(7):865–871CrossRef PubMed
16.Møller JE, Dahlström U, Gøtzsche O, Lahiri A, Skagen K, Andersen GS, Egstrup K, OPTIMAAL Study Group (2004) Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the optimal trial in myocardial infarction with angiotensin II antagonist losartan (OPTIMAAL) echocardiographic substudy. Am Heart J 147(3):494–501CrossRef PubMed
17.Raczek KK, Dorey F, Wong PC, Szmuszkovicz JR, Menteer J (2010) Relative versus absolute values: using patient and population norms for echocardiography in pediatric cardiac transplant recipients. Pediatr Transplant 14(2):182–187CrossRef PubMed
18.Ramaciotti C, Heistein LC, Coursey M, Lemler MS, Eapen RS, Iannaccone ST, Scott WA (2006) Left ventricular function and response to enalapril in patients with duchenne muscular dystrophy during the second decade of life. Am J Cardiol 98(6):825–827CrossRef PubMed
19.Schram G, Fournier A, Leduc H, Dahdah N, Therien J, Vanasse M, Khairy P (2013) All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. J Am Coll Cardiol 61(9):948–954CrossRef PubMed
20.Townsend D, Yasuda S, McNally E, Metzger JM (2011) Distinct pathophysiological mechanisms of cardiomyopathy in hearts lacking dystrophin or the sarcoglycan complex. FASEB J 25(9):3106–3114CrossRef PubMed PubMedCentral
21.Wagner S, Knipp S, Weber C, Hein S, Schinkel S, Walther A, Bekeredjian R, Müller OJ, Friedrich O (2012) The heart in Duchenne muscular dystrophy: early detection of contractile performance alteration. J Cell Mol Med 16(12):3028–3036CrossRef PubMed PubMedCentral
22.Williams IA, Allen DG (2007) Intracellular calcium handling in ventricular myocytes from mdx mice. Am J Physiol Heart Circ Physiol 292:H846–H855CrossRef PubMed
23.Woolf PJ, Lu S, Cornford-Nairn R, Watson M, Xiao XH, Holroyd SM, Brown L, Hoey A (2006) Alterations in dihydropyridine receptors in dystrophin-deficient cardiac muscle. Am J Physiol Heart Circ Physiol 290:H2439–H2445CrossRef PubMed
24.Yasuda S, Townsend D, Michele DE, Favre EG, Day SM, Metzger JM (2005) Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 436(7053):1025–1029CrossRef PubMed - 作者单位：Jennifer A. Su (1) (2)
Leigh Ramos-Platt (2) (3)
JonDavid Menteer (1) (2)
1. Division of Cardiology at Children’s Hospital of Los Angeles, Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
2. Children’s Hospital of Los Angeles, 4650 W. Sunset Blvd, Mailstop #34, Los Angeles, CA, 90027, USA
3. Division of Neurology at Children’s Hospital of Los Angeles, Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA - 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Cardiology
Cardiac Surgery
Vascular Surgery - 出版者：Springer New York
- ISSN：1432-1971
文摘
Dilated cardiomyopathy (DCM) inevitably afflicts patients with Duchenne muscular dystrophy (DMD) as a consequence of cell death induced by unguarded calcium influx into cardiomyocytes. This mechanism may also inhibit muscle relaxation in early stages of cardiomyopathy. ACE inhibition (ACEi) is known to delay the onset and slow the progression of DCM in DMD. The objective of this study is to use echocardiography to assess for preclinical cardiac changes consistent with intracellular calcium dysregulation before the onset of overt ventricular dysfunction, and to evaluate how prophylactic ACEi may alter these pre-cardiomyopathic changes in the pediatric DMD population. We examined 263 echocardiograms from 70 pediatric patients with DMD. We defined abnormal tonic contraction (TC) as left ventricular internal dimension in diastole (LVIDd) Z-score < −1.5. In our cohort, we found that TC is detectable as early as 8 years of age, and most commonly affects patients between 11 and 15 years. This effect was independent of LV mass and systolic function. Prophylactic ACEi decreased the incidence of TC (p = 0.007) and preserved cardiac function (p < 0.0001). Left ventricular TC often precedes DCM in DMD, most commonly affecting the 11- to 15-year-old age range. TC is not related to ventricular hypertrophy, but rather may be a clinical correlate of the “calcium hypothesis” of DMD pathophysiology. LV TC is thus a promising biomarker for early detection of cardiomyopathy in DMD. ACEi prophylaxis suppresses LV TC and delays the development of DCM in DMD.